Fig. 1.

Baseline characteristics of the entire study cohort including 1,021 glioblastoma patients. (A) Schematic localization of the 7 participating neuro-oncological centers. (B–D) Distribution of IDH mutation status (B), MGMT promotor status (C), and first-line therapies (D) across the entire study cohort (n = 1,021). (E–H) Kaplan–Meier estimates of progression-free survival (E and G) and OS (F and H) for the entire study cohort (n = 1,021). Curves are given for patients stratified according to the respective study center (E and F) and MGMT promotor status (G and H). Points: deceased/censored patients; shading: SEM.